For research use only. Not for therapeutic Use.
SB 258719 is a selective 5-HT7 receptor antagonist with high affinity (pKi=7.5) for the receptor. SB 258719 can be used for the research of cancer and neurological disease[1][2][3].
SB 258719 (1, 3 and 10 μM; HEK 293 cells) produces a concentration-related rightward-shift of the 5-CT concentration-response curve with no signifcant alteration in the maximal response to 5-CT[1].
SB 258719 (5-20 mg/kg; i.p.) significantly attenuates the 5-CT-induced hypothermia[2].
| Catalog Number | M046205 |
| CAS Number | 195199-95-2 |
| Synonyms | N,3-dimethyl-N-[(2R)-4-(4-methylpiperidin-1-yl)butan-2-yl]benzenesulfonamide |
| Molecular Formula | C18H30N2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C18H30N2O2S/c1-15-8-11-20(12-9-15)13-10-17(3)19(4)23(21,22)18-7-5-6-16(2)14-18/h5-7,14-15,17H,8-13H2,1-4H3/t17-/m1/s1 |
| InChIKey | AGVNHDNTFYHZNL-QGZVFWFLSA-N |
| SMILES | CC1CCN(CC1)CCC(C)N(C)S(=O)(=O)C2=CC=CC(=C2)C |
| Reference | [1]. Thomas DR, et al. Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol. 1998;124(6):1300-1306. [2]. Guscott MR, et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003;44(8):1031-1037. [3]. Fatima S, et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin. Mol Oncol. 2016;10(2):195-212. |
